Aduro has completed the formal analysis of the randomized, controlled Phase 2 clinical trial of the sequential administration of two cancer vaccines, GVAX Pancreas and CRS-207, in patients with metastatic pancreatic cancer (ClinicalTrials.gov Identifier: NCT01417000). 

 

May 20, 2013
Aduro Announces Poster Presentations of Phase 2 Pancreatic Cancer and Phase 1B Mesothelioma Clinical Trials at ASCO. Read it here.

May 8, 2013
Aduro scientific advisory board member Daniel A. Portnoy elected to the National Academy of Sciences. Read it here.

 

April 22, 2013
Aduro announces collaboration with Johns Hopkins University to evaluate Aduro therapeutic melanoma vaccines in combination with anti-PD-1. Read it here.

 

April 5, 2013
Aduro announces upcoming presentations on oncology programs at American Association of Cancer Research meeting. Read it here.

 

February 4, 2013
Aduro announces acquisition of GVAX assets from BioSante. Read it here.